anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators propose to refine and then evaluate a novel transition support and intervention program for adolescents and young adults with ASD: STEPS \[Stepped Transition in Education Program for Students with ASD\]. By targeting improved self-regulation (SR) and self-determination (SD) in young people with ASD, the investigators assert that this program may have positive outcomes with respective to college adjustment and functional behavior. Although the program will be finalized during the first phase of the proposed project, at present STEPS is comprised of two levels (or steps), which match the student's particular needs in relation to transition planning. In Step 1, students facing transition (i.e., have identified the college they will attend (either 2-year or 4-year institution) but are still in high school) and their caregivers will receive information to assist in transition planning, undergo readiness self-assessments (to identify degree of preparedness for post-secondary school), and participate in interactive sessions online and in person to promote self-knowledge and determination. The goal of Step 1 is to assist families and students with transition planning, specifically ensuring that families and students have the tools needed to make informed choices and take necessary steps (e.g., remediating identified skill deficits) to increase the likelihood of a successful transition out of high school. In Step 2, college students with ASD will receive fairly intensive supports and interventions, including individual counseling, structured support services, social integration activities, and coaching to promote academic and social success. The following specific aims are proposed.
Patients will then receive, in a randomized double-blinded fashion, levalbuterol, 1.25mg every 20 minutes for a total of 3 aerosolized doses combined with ipratropium, 0.5mg every 20 minutes for a total of 3 aerosolized doses. The medication will be premixed by the pharmacy in a total of 3 ml of normal saline and the nebulizer will be driven with oxygen at 6 liters per minute. A second plasma sample for analysis of albuterol isomers will be drawn within a fifteen minute window following the third aerosol treatment. Spirometry will be repeated again at 30 and 60 minutes after the third aerosol treatment (Figure 1). All patients will receive prednisone, 60mg orally immediately after their first dose of aerosolized medications, unless contraindications to prednisone administration are present. Patients will not receive any other medications during the time course of the study. Vital signs and pulse oximetry will be repeated prior to each nebulized treatment and again 30 minutes after the third nebulized treatment.

The study will terminate 60 minutes after the third aerosol administration. At that point, any further therapy will be at the discretion of the treating physician. Patients will be questioned about the occurrence of any side effects from levalbuterol treatment including palpitations, anxiety, nausea, vomiting or headache. Patients will also be questioned about the occurrence of any side effects from ipratropium, including dry mouth, dry eyes, and urinary retention. Patients will be withdrawn from the study at any point these side effects become intolerable to the patient or any time the patient so desires. Patients will also be withdrawn if they develop palpitations and have an ECG that demonstrates ventricular or supraventricular tachycardia.

.Patients will be called 14 days after their ED visit to assess relapse or recurrence of acute asthma exacerbation. In addition, a chart review will be performed to assess relapse or recurrence of acute asthma exacerbation, as well as determine hospital length of stay in those patients who required admission after the initial visit.
Venetoclax was administered orally once daily (QD) for a planned duration of up to 2 years or until disease progression; median time on treatment was 127 weeks. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
PROBLEM TO BE SOLVED: To effectively utilize long-stored raw rice (one or two years long) as a healthy food having balanced nutrients, and provide an anticancer agent and a feed. SOLUTION: A liquid produced by extracting bamboo or bamboo-grass leaf with an acidic or alkaline liquid is added to the long-stored raw rice to form green rice, which is cooked and formed in a rice ball. The rice ball enriched with amino acids and vitamins is produced by this process. An imitation laver is produced by mixing seasonings, spices, miso and soy sauce powder to non- chlorella, chlorella, enzyme, spore of Ganoderma lucidum, (fruit of Momordica grosvenori), fermented bean curd refuse, stevia tea powder, fermented ginkgo leaf, rhizome of Panax notiginseng and tea powder. The mixture is formed in a film by using a fermented starch as a base material. The rice ball is wrapped with the imitation laver to obtain a healthy food. A healthy drink, an anticancer agent or a feed can be produced by formulating the fruit of Momordica grosvenori and spore of Ganoderma lucidum.
The invention discloses a rhinitis treatment Chinese patent drug for direct nasal lavage and oral administration. 15g of the rhinitis treatment Chinese patent drug composed of particles are extracted from 6g of houttuynia cordata, 8g of flos magnoliae liliflorae, 6g of radix angelicae, 6g of Chinese angelica, an appropriate amount of medicinal dextrin and 5g of honey by the existing Chinese patent drug preparation technology. Each 15g of the rhinitis treatment Chinese patent drug is sealed into a small bag by a composite membrane. Multiple small bags are sealed into a big plastic bag. Each small bag of the rhinitis treatment Chinese patent drug is mixed with 600g of water and then is cooled for next use. In nasal lavage, rhinitis treatment Chinese patent drug-containing warm water in a bowl is sucked and injected by nostrils many times; the rhinitis treatment Chinese patent drug-containing warm water is sucked into the throat and is spat by the mouth many times; after the rhinitis treatment Chinese patent drug-containing warm water is sucked by the nose, the two nostrils are pinched by fingers; the head pitches up and then the two nostrils are pinched and released many times by two fingers; the head is bent and then the rhinitis treatment Chinese patent drug-containing warm water is injected; and suction and injection are repeated many times. The small bag of the rhinitis treatment Chinese patent drug can be mixed with boiling water and the rhinitis treatment Chinese patent drug-containing boiling water can be used as tea for drinking. The rhinitis treatment Chinese patent drug can be used for direct nasal lavage and oral administration and can treat diseases in the nose.
Sjögren's syndrome (SS) or Sjögren's disease (SjD) is a systemic autoimmune disease clinically manifested as sicca symptoms. This disease primarily impacts the functionality of exocrine glands, specifically the lacrimal and salivary glands (SG). SG fibrosis, an irreversible morphological change, is a severe consequence that occurs in the later stages of the disease due to sustained inflammation. However, the mechanism underlying SG fibrosis in SS remains under-investigated. Glandular fibrosis may arise from chronic sialadenitis, in which the interactions between infiltrating lymphocytes and epithelial cells potentially contributes to fibrotic pathogenesis. Thus, both immune and non-immune cells are closely involved in this process, while their interplays are not fully understood. The molecular mechanism of tissue fibrosis is partly associated with an imbalance of immune responses, in which the transforming growth factor-beta (TGF-β)-dependent epithelial-mesenchymal transition (EMT) and extracellular matrix remodeling are recently investigated. In addition, viral infection has been implicated in the pathogenesis of SS. Viral-specific innate immune response could exacerbate the autoimmune progression, resulting in overt inflammation in SG. Notably, post-COVID patients exhibit typical SS symptoms and severe inflammatory sialadenitis, which are positively correlated with SG damage. In this review, we discuss the immune and non-immune risk factors in SG fibrosis and summarize the evidence to understand the mechanisms upon autoimmune progression in SS.
The present invention relates to a medicine for treating hypernlasia of the mammary gland, which belongs to the field of a Chinese medicine. The medicine is prepared from Chinese medicines of the following proportion by weight: 5 to 15 of milkvetch root, 10 to 20 of red sage root, 5 to 15 of white peony root, 5 to 15 of green tangerine peel, 10 to 20 of Chinese angelica, 2 to 10 of catclaw buttercup root, 5 to 15 of corydalis tuber, 5 to 15 of nutgrass galingale rhizome, 10 to 20 of snakegourd fruit and 5 to 15 of bupleurum root. The medicine has the efficiency of coursing the liver, rectifying qi, nourishing the blood and liver, dispersing swelling and relieving pain. Most patients have a good impression on the medicine for several years, and the curative effects of the medicine are as good as those of the Chinese patent medicines in the market, such as Rukangpian, Rupixiao, Ruzengning, Ruhesanjiepian, etc. From 1996 till now, 4819 patients are cured in total. The clinical observation proves that the medicine of the present invention has unique curative effects on various kinds of hypernlasia of the mammary gland and generates good social benefit and economic benefit.
Choroidal neovascularization (CNV) represents a hallmark of neovascular fundus diseases, including age-related macular degeneration and diabetic retinopathy. Traditional eyedrops have encountered formidable challenges in treating CNV, primarily due to their extremely poor intraocular bioavailability and potential adverse off-target effects. Herein, an ocular-permeable supramolecular prodrug eyedrop (Di-DAS/P-PCD) has been developed for the on-demand delivery of antiangiogenic agents in the oxidative microenvironment of CNV. The eyedrop nanoformulation is composed of cell-penetrating peptide-modified PEGylated cyclodextrin (P-PCD) and reactive oxygen species (ROS)-sensitive antiangiogenic dasatinib prodrug Di-DAS. In a laser-induced CNV mouse model, daily instillation of Di-DAS/P-PCD has achieved remarkable penetration into the choroid and significantly suppressed CNV growth while exhibiting a good biocompatibility profile. Our results highlight the potential of the supramolecular prodrug eyedrops as a versatile approach for the targeted treatment of CNV and other neovascular eye disorders.
BACKGROUND: Meniscectomy, whether partial or total, is a common knee surgery, but it considerably increases the risk of knee osteoarthritis (OA). Lateral meniscectomy has more severe consequences than medial meniscectomy, leading to faster OA progression and worse clinical outcomes. Unicompartmental knee arthroplasty (UKA) is a suitable treatment option for lateral OA and has demonstrated better outcomes than total knee arthroplasty (TKA). The aims of this study were to evaluate the clinical and functional results, OA progression in the medial compartment, and implant survivorship following lateral UKA in patients with OA secondary to lateral meniscectomy and to compare these outcomes with those of patients who underwent lateral UKA for primary lateral OA.
METHODS: Between 2001 and 2017, 214 lateral UKAs were performed. Of these, 42 were performed for OA secondary to lateral meniscectomy. The control group was composed of patients who underwent lateral UKA for primary lateral OA and was formed through a 1:1 case-control matching process based on sex, age, body mass index, and operation date. The outcomes that were studied included range of motion, Knee Society Score, University of California Los Angeles (UCLA) Activity Score, Tegner Activity Scale, Forgotten Joint Score, visual analog scale for pain, OA progression in the medial compartment, and implant survivorship.
RESULTS: At a mean follow-up of 10.2 years, both groups demonstrated significant improvements (p < 0.01) after lateral UKA in all clinical and functional scores except the UCLA Activity Score and Tegner Activity Scale. No significant differences in clinical and functional scores were found between the groups. However, patients with OA secondary to meniscectomy exhibited significantly less OA progression in the medial compartment (p = 0.035) and higher 10-year implant survival (97.6% versus 83.3%).
CONCLUSIONS: Lateral UKA is an effective treatment option for OA secondary to lateral meniscectomy, providing excellent functional outcomes and survivorship. Patients with post-meniscectomy OA exhibited less OA progression in the medial compartment than patients with primary OA and, consequently, had better 10-year implant survivorship.
LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Controls will have their olfactory functioning assessed at baseline and 6 weeks after the baseline assessment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
PCT No. PCT/JP94/02227 Sec. 371 Date Aug. 25, 1997 Sec. 102(e) Date Aug. 25, 1997 PCT Filed Dec. 27, 1994 PCT Pub. No. WO95/18221 PCT Pub. Date Jul. 6, 1995A DNA containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:4 or 6 in Sequence Listing, which optionally has partial replacement, deletion or addition, or a base sequence hybridizable therewith; a recombinant vector containing this gene; a transformant constructed by using this vector; a process for producing adseverin by using the above-mentioned gene; a recombinant adseverin protein obtained by this production process; an oligonucleotide hybridizable specifically with a base sequence encoding an amino acid sequence represented by SEQ ID NO:4 or 6; a method for regulating the formation of adseverin in an animal which comprises administering the above-mentioned oligonucleotide to the animal; and an antibody capable of recognizing adseverin protein.
PURPOSE: A cream containing an Ulmus davidiana var. japonica extract for treating atopic dermatitis is provided to effectively treat atopic dermatitis. CONSTITUTION: A method for manufacturing a cream composition for treating atopic dermatitis comprises the steps of: pulverizing Ulmus davidiana var. japonica in a size of 0.3-3 um and mixing with glycerin and water; centrifuging the dissolved liquid at 3000 rpm for 30 minutes; separating a supernatant to obtain an aqueous layer and heating the aqueous layer; mixing Vaseline, cetyl alcohol, beeswax, lecithin, and a natural antiseptic, preparing an oil layer, and heating the oil layer; and mixing the aqueous layer and the oil layer. [Reference numerals] (AA) Pulverizing Ulmus davidiana var. japonica; (BB) Ulmus davidiana var. japonica powder/dissolving, Centrifuging; (CC) Separating the supernatant; (DD) Mixing Vaseline cetyl alcohol, beeswax, lecithin, and a natural antiseptic; (EE) Producing a cream
PROBLEM TO BE SOLVED: To obtain the subject composition which can reinforce the intraocular pressure-lowering action of angiotensin II antagonist and can efficiently lower an intraocular pressure raised by glaucoma, hypertonia bulbi, or the like, by adding boric acid and ethylenediaminetetraacetic acid to the angiotensin II antagonist. SOLUTION: This intraocular pressure-lowering composition for topical administration comprises (A) an angiotensin II antagonist, (B) a boric acid compound, and (C) an ethylenediamine tetraacetic acid compound. The component A includes a compound of formula I (R1 is a group of formula II, a group of formula III or the like). The compound of formula I preferably includes 4-(1- hydroxy-1-methylethyl)-2-propyl-1- 4-[2-(tetrazol-5-yl)phenyl]phenyl) methylimidazole-5-carboxylic acid. The composition preferably contains paraben or the like as a preservative. The composition can be used in a dosage form, such as an (aqueous) eye drop or an eye ointment, suitable for topical administration to eyes.
This arm will receive enough oil to prepare the CSB they receive in the newly recommended proportion of 100g CSB: 30g oil. They will receive education and instructions on the new method of preparation.
A new process is described for the synthesis of the triazolyl tryptamine (.alpha.) and related compounds. The process involves a palladium-catalyzed ring closure between a substituted ortho-iodoaniline and a protected 1-alkynol. The process is carried out at high temperature, e.g. 100 ~C, in a dry inert solvent, e.g., DMF and in the presence of a proton acceptor, e.g., Na2CO3 or a trialkylamine. The triazolyl tryptamine, as well as acid addition salts thereof, is a 5 HT1D receptor agonist having anti-migraine properties.
Tourette's disorder (TD) is a chronic, childhood-onset neuropsychiatric disorder. It is characterized by multiple motor and vocal tics, including involuntary or semivoluntary, sudden, brief, intermittent, repetitive movements or sounds. Yigansan was used in several clinical trials, like dementia, pervasive developmental disorder, schizophrenia and Huntington's disease, with good results. So the investigators choose Yigansan as a Chinese medicine formula in this study. After the participants signed the consent form, they have to stop taking any Chinese medicine or western medicine for treating Tourette's disorder for two weeks and then are randomly assigned to Yigansan group or placebo group. Our hypothesis is that Yigansan will be expected to improve motor tics and vocal tics, and YGTSS scores will decrease after 4-weeks treatments; secondary outcomes are measured by CGI-TS (Clinical Global Impression-Tourette Syndrome) scale and GTS-QOL (The Gilles de la Tourette syndrome-quality of life scale), and the investigators will also proceed the basic research of metabolomics and biochemistry(GOT、GPT、BUN、Creatinine、K+). In order to ensure the relationship of Tourette's disorder and allergic rhinitis, the investigators will detect IgE. Besides, the investigators will collect blood and urine from every child or adolescent when a participant visits our clinic at week 0 and week 4. In order to find these biomarkers related to TD, the investigators will use ELISA kits to detect and quantitate significantly changeable concentration of cytokines associated with YGTSS scores. In addition to specific cytokine targets, the investigators will also find these metabolites involved in TD between two groups before and after taking YGS. The serum and urine samples will be prepared and subjected to LC-MS/MS analysis. In summary of the experimental designs and expected results, the therapy and background information will be more clarified on the therapeutic efficacy and safety by Yigansan treatment for TD. Most importantly, this study will provide a kind of Chinese medicine formula to relieve such a disorder that most doctors feel difficult to treat.
BACKGROUND: The association between body mass index (BMI) and mortality among individuals with renal cell cancer (RCC) is debated, with some observational studies suggesting a lower mortality associated with higher BMI. However, methodological issues such as confounding and reverse causation may bias these findings. Using BMI-associated genetic variants can avoid these biases and generate more valid estimates.
METHODS: In this prospective cohort study, we included 1264 RCC patients (446 deaths) from the UK Biobank. We created a BMI polygenic score (PGS) based on 336 BMI-associated genetic variants. The association between the PGS and mortality (all-cause and RCC-specific) was evaluated by logistic regression (all RCC cases) and Cox regression (906 incident cases). For comparison, the associations of measured pre-diagnostic BMI and waist-to-hip ratio (WHR) with mortality were quantified by Cox regression among incident cases. We stratified these analyses by time between anthropometric measurement and RCC diagnosis to assess the influence of reverse causation.
RESULTS: We did not observe an association between the BMI PGS and all-cause mortality among RCC patients (hazard ratio (HR) per SD increase = 0.98, 95% CI: 0.88,1.10). No association was found for pre-diagnostic BMI (HR per 5 kg/m2 increase = 0.93, 95% CI: 0.83,1.04) or WHR (HR per 0.1 increase = 0.97, 95% CI: 0.83,1.13) with mortality. In patients with anthropometrics measured within 2 years before RCC diagnosis, we observed associations of higher BMI (HR per 5 kg/m2 = 0.76, 95% CI: 0.59,0.98) and WHR (HR = 0.67 per 0.1 increase, 95% CI: 0.45,0.98) with a lower risk of death. Similar patterns were observed for RCC-specific mortality.
CONCLUSION: We found no association between either genetic variants for high BMI or measured pre-diagnostic body adiposity and mortality among RCC patients, and our results suggested a role for reverse causation in the association of obesity with lower mortality. Future studies should be designed carefully to produce unbiased estimates that account for confounding and reverse causation.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention describes tablets with envelope and without envelope used as inhibitors of cholesterol for oral intake. Tablets have anion-exchange resin of the formula (I):   where X means physiologically acceptable anti-ion; p means mean degree of polymerization but above 10 000 Da; silicon dioxide and crystalline cellulose but they have no water. The made tablets without envelope are covered by cellulose substances preferably. Invention provides making tablets that can be intaken easily since they have no bitter principle. Dose of tablets to be intaken can be decreased since tablets can have a large dose of active component. Mixture containing components can be tableted easily in the presence of water. EFFECT: improved properties of composition and tablets, improved method of making. 10 cl, 2 tbl
A composition comprising emulsifying ointment and water substantially in the proportions A% and B% respectively of the total composition, where the ratio A:B is in the range 60:40 to 30:70 and A+B is in the range 100% to 95% w/w of the total composition. The balance, if any, is one or more substances in a total proportion C% of the total composition, where C% is not more than 5% w/w, in which the emulsifying ointment comprises emulsifying wax made of cetostearyl alcohol and polysorbate 60. The C% may consist solely of preservative, eg phenoxyethanol. The proportion of polysorbate 60 in the emulsifying wax may be in the range 19 to 23%. A method of making the composition comprises heating the emulsifying ointment and water to substantially 60Â°C, stirring and cooling. The composition may be used as a pharmaceutical, or as a non-pharmaceutical composition, for example a soap, emollient and/or moisturiser.